•A subset of patients with uterine carcinosarcoma will have ER/PR positive disease.•Hormone receptor expression may serve as a therapeutic target in high-grade endometrial tumors.•Hormonal therapy and SBRT may have benefit in the management of recurrent uterine carcinosarcoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651896 | PMC |
| http://dx.doi.org/10.1016/j.gore.2021.100877 | DOI Listing |
Publication Analysis
Top Keywords
uterine carcinosarcoma
12
progestin aromatase
4
aromatase inhibitor
4
inhibitor therapy
4
therapy recurrent
4
recurrent estrogen/progestin
4
estrogen/progestin receptor
4
receptor positive
4
positive uterine
4
carcinosarcoma case
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!